Lisa Li Zhu, MD
Rheumatology · Encino
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 8
Offices
8 locations · The Regents of the University of California · 1,426 clinicians in this group
Hospitals listed: Ronald Reagan UCLA Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Zhu’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A143695 · Current
Licensed to practise in California · since 2016 · expires 2027-12-31 · David Geffen School of Medicine at UCLA.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Ronald Reagan UCLA Medical CenterLos Angeles, CAAcute Care Hospital · Government - State · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Jonsson Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.27 (4.69 to 7.85) · 3,570 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 5.17 (1.78 to 8.56) · 1,778 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.21 (0 to 0.62) · 8,165 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.59, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.611, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.503, Oct 2024 – Sep 2025
See every measure and the patient survey for Ronald Reagan UCLA Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.27 (4.69 to 7.85) · 3,570 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.17 (1.78 to 8.56) · 1,778 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.62) · 8,165 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.59 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.611 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.503 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.67 (0 to 1.44) · 2,883 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.7 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.14 (139.88 to 202.41) · 282 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 122 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.5 · 107 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 350 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.1 · 436 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.8 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.4 · 3,004 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 9,102 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.09 to 0.44) · 10,460 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0.57 to 2.77) · 1,972 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.27 to 3.44) · 3,000 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.93 (3.76 to 8.09) · 2,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.65 (1.31 to 3.98) · 1,032 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.56 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.626 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 138 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 357 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -7.1 · 122 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -12.9 · 385 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.6 · 427 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.7 to 6.5) · 609 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (10.1 to 15) · 609 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.8 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.5 to 13.7) · 2,701 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,463 cases | No different | Jan 2024 – Dec 2024 |
What patients said (814 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$154,584
Medicare paid this office $154,584 for 257 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 19 | $42,355 | None |
| Return visit (30+ min) | 180 | $34,301 | $100 |
| New patient visit (45+ min) | 60 | $7,822 | $130 |
| Long return visit (40+ min) | 27 | $4,299 | $143 |
| New patient visit (60+ min) | 21 | $3,766 | $179 |
See all 10 services
| Injection, denosumab, 1 mg | 19 | $42,355 | None |
| Return visit (30+ min) | 180 | $34,301 | $100 |
| New patient visit (45+ min) | 60 | $7,822 | $130 |
| Long return visit (40+ min) | 27 | $4,299 | $143 |
| New patient visit (60+ min) | 21 | $3,766 | $179 |
| Short return visit (20+ min) | 39 | $3,264 | $71 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 117 | $2,820 | $13 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,552 | $62 |
| Injection of drug or substance under skin or into muscle | 24 | $655 | $11 |
| Injection, methylprednisolone acetate, 1 mg | 21 | $119 | None |
Who their Medicare patients are
257 Original Medicare patients in 2024. Average age 71 · Under 65 13% · 85 and older 7% · Women 73% · Also on Medicaid 27% · Health risk score 1.51. Above the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 66% · Depression 33% · Diabetes 31% · Coronary heart disease 31% · Chronic kidney disease 20% · COPD 20% · Cancer 19% · Heart failure 15% · Atrial fibrillation 12% · Stroke 11% · Dementia 7%.
The office billed $1,039,596, Medicare allowed $199,475 and paid $154,584; for 9,645 services of 28 kinds; $91,728 of it was for drugs given in the office and $62,856 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 257 | 9,645 | 71 | 1.51 | $1,039,596 | $154,584 |
| 2023 | 154 | 2,317 | 73 | 1.54 | $418,969 | $60,029 |
| 2022 | 236 | 1,557 | 72 | 1.37 | $573,073 | $78,980 |
| 2021 | 117 | 566 | 72 | 1.42 | $240,818 | $33,221 |
| 2020 | 26 | 62 | 72 | 1.49 | $29,894 | $5,651 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Injection, denosumab, 1 mg | 12 | $20,122 | None |
| Return visit (30+ min) | 96 | $16,813 | $101 |
| New patient visit (45+ min) | 42 | $5,351 | $127 |
| Long return visit (40+ min) | 18 | $3,218 | $140 |
| Short return visit (20+ min) | 17 | $1,547 | $74 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,528 | $57 |
| Injection of drug or substance under skin or into muscle | 14 | $293 | $12 |
| Injection, methylprednisolone acetate, 40 mg | 18 | $184 | None |
2022: 7 services
| Return visit (30+ min) | 119 | $24,158 | $103 |
| New patient visit (45+ min) | 108 | $13,952 | $129 |
| Aspiration and/or injection of fluid from large joint | 33 | $4,698 | $57 |
| Long return visit (40+ min) | 28 | $4,415 | $152 |
| Short return visit (20+ min) | 26 | $2,437 | $70 |
| Return visit (30+ min) | 12 | $928 | $71 |
| Injection, methylprednisolone acetate, 40 mg | 25 | $170 | None |
2021: 5 services
| Return visit (30+ min) | 44 | $10,430 | $109 |
| New patient visit (45+ min) | 57 | $7,787 | $137 |
| Long return visit (40+ min) | 20 | $3,196 | $152 |
| New patient visit (60+ min) | 12 | $2,014 | $168 |
| Aspiration and/or injection of fluid from large joint | 12 | $1,472 | $51 |
2020: 2 services
| Return visit (30+ min) | 12 | $2,131 | $97 |
| New patient visit (45+ min) | 13 | $1,889 | $145 |
Drugs they prescribed that Part D paid
$911,967
Pharmacies billed $911,967 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (27 of 1,067) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
879 generic and 188 brand-name prescriptions · $911,967 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira | 18 | $204,406 | $11,356 |
| Rinvoq | 21 | $127,416 | $6,067 |
| Xeljanz | 12 | $69,542 | $5,795 |
| Hydroxychloroquine Sulfate | 123 | $5,984 | $49 |
| Leflunomide | 61 | $3,558 | $58 |
See all 24 drugs
| Humira | 18 | $204,406 | $11,356 |
| Rinvoq | 21 | $127,416 | $6,067 |
| Xeljanz | 12 | $69,542 | $5,795 |
| Hydroxychloroquine Sulfate | 123 | $5,984 | $49 |
| Leflunomide | 61 | $3,558 | $58 |
| Methotrexate | 72 | $3,207 | $45 |
| Mycophenolate Mofetil | 18 | $2,206 | $123 |
| Sulfasalazine Dr | 35 | $1,800 | $51 |
| Colchicine | 20 | $1,413 | $71 |
| Duloxetine | 32 | $1,286 | $40 |
| Diclofenac | 41 | $871 | $21 |
| Prednisone | 94 | $785 | $8 |
| Gabapentin | 43 | $723 | $17 |
| Pregabalin | 31 | $578 | $19 |
| Celecoxib | 25 | $487 | $19 |
| Allopurinol | 42 | $388 | $9 |
| Folic Acid | 12 | $291 | $24 |
| Alendronate | 26 | $289 | $11 |
| Tramadol | 18 | $242 | $13 |
| Meloxicam | 39 | $149 | $4 |
| Cyclobenzaprine | 12 | $125 | $10 |
| Methylprednisolone | 20 | $108 | $5 |
| Leucovorin | 14 | $72 | $5 |
| Alprazolam | 11 | $15 | $1 |
Year by year
| 2024 | 1,067 | 266 | 3% (27) | 18% | $911,967 |
| 2023 | 571 | 181 | 5% (29) | 12% | $201,785 |
| 2022 | 806 | 224 | 4% (32) | None | $221,913 |
| 2021 | 414 | 117 | 5% (21) | 9% | $119,572 |
| 2020 | 91 | 44 | None | None | $29,664 |
| 2019 | 69 | 14 | 0% (0) | 28% | $70,166 |
| 2018 | 26 | None | 0% (0) | None | $57,577 |
| 2017 | 13 | None | None | None | $447 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Hydroxychloroquine Sulfate | 75 | $4,143 | $55 |
| Methotrexate | 33 | $2,105 | $64 |
| Diclofenac | 58 | $1,562 | $27 |
| Sulfasalazine Dr | 21 | $1,117 | $53 |
| Leflunomide | 18 | $992 | $55 |
| Prednisone | 72 | $990 | $14 |
| Gabapentin | 32 | $960 | $30 |
| Colchicine | 14 | $928 | $66 |
| Duloxetine | 12 | $652 | $54 |
| Alendronate | 15 | $348 | $23 |
| Tramadol | 19 | $315 | $17 |
| Allopurinol | 22 | $260 | $12 |
| Celecoxib | 13 | $223 | $17 |
| Meloxicam | 13 | $121 | $9 |
2022: 17 drugs
| Actemra | 11 | $37,490 | $3,408 |
| Hydroxychloroquine Sulfate | 107 | $5,720 | $53 |
| Methotrexate | 54 | $3,765 | $70 |
| Colchicine | 24 | $3,603 | $150 |
| Diclofenac | 83 | $2,595 | $31 |
| Leflunomide | 16 | $1,766 | $110 |
| Sulfasalazine Dr | 27 | $1,425 | $53 |
| Prednisone | 138 | $1,201 | $9 |
| Duloxetine | 36 | $1,104 | $31 |
| Gabapentin | 52 | $973 | $19 |
| Allopurinol | 45 | $721 | $16 |
| Pregabalin | 14 | $633 | $45 |
| Celecoxib | 11 | $244 | $22 |
| Pantoprazole | 14 | $181 | $13 |
| Alendronate | 14 | $167 | $12 |
| Hydrocodone-Acetaminophen | 16 | $114 | $7 |
| Meloxicam | 13 | $22 | $2 |
2021: 8 drugs
| Colchicine | 27 | $3,218 | $119 |
| Diclofenac | 27 | $1,914 | $71 |
| Hydroxychloroquine Sulfate | 30 | $1,706 | $57 |
| Methotrexate | 31 | $1,653 | $53 |
| Prednisone | 91 | $977 | $11 |
| Allopurinol | 15 | $152 | $10 |
| Gabapentin | 17 | $117 | $7 |
| Tramadol | 11 | $48 | $4 |
2020: 1 drug
| Prednisone | 23 | $241 | $10 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 86.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1235524596
- Licence
- CA A143695California A143695: Current · expires 2027-12-31
- Trained
- University of California, Geffen School of Medicine, 2015
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Student in a training program (390200000X)
- Mailing address
- 5767 W Century Blvd Ste 400, Los Angeles, CA, 90045
- NPI first listed
- 2015-04-03
- NPI last updated
- 2020-12-15
- NPI record certified
- 2020-12-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305